Company: DARE
Filing Date: 2025-04-24
Form Type: ARS
Source: 0001401914-25-000018
Chunk: 268

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: ARS
Chunk 268
---
 548,638 468,726 Total current liabilities 21,609,013 20,480,436 Deferred revenue, non-current 1,000,000 1,000,000 Liability related to the sale of future royalties, net 4,749,824 3,913,676 Lease liabilities, non-current 754,383 935,743 Total liabilities 28,113,220 26,329,855 Commitments and contingencies (Note 14) Stockholders' deficit Preferred stock, $0.01 par value, 5,000,000 shares authorized None issued and outstanding — — Common stock, $0.0001 par value, 240,000,000 shares authorized, 8,700,386 and 8,331,161 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively 870 833 Additional paid-in capital 169,705,480 166,548,454 Accumulated other comprehensive loss (428,809) (360,896) Accumulated deficit (175,289,630) (171,236,031) Total stockholders' deficit (6,012,089) (5,047,640) Total liabilities and stockholders' deficit $ 22,101,131 $ 21,282,215 See accompanying notes. F-4

Daré Bioscience, Inc. and Subsidiaries Consolidated Statements of Operations and Comprehensive Loss Years Ended December 31, 2024 2023 Revenue License fee revenue $ — $ 1,000,000 Milestone revenue — 1,800,000 Royalty revenue 9,784 7,885 Total revenue 9,784 2,807,885 Operating expenses General and administrative 9,156,061 12,109,691 Research and development 14,205,208 21,538,074 License fee expense 100,000 100,000 Total operating expenses 23,461,269 33,747,765 Loss from operations (23,451,485) (30,939,880) Other income (expense) Sale of royalty and milestone rights, net of transaction costs (Note 13) 20,379,376 — Other (expense) income (981,490) 778,489 Net loss $ (4,053,599) $ (30,161,391) Net loss to common stockholders $ (4,053,599) $ (